Articles tagged with: Sarclisa
Press Releases»
- Study evaluated the benefit of isatuximab in combination with standard of care in prolonging progression free survival as compared to standard of care in patients with relapsed / refractory multiple myeloma
- First randomized Phase 3 trial to evaluate the benefit of adding a monoclonal antibody to pomalidomide and dexamethasone for treatment of relapsed / refractory multiple myeloma
- Multiple ongoing Phase 3 studies with isatuximab, an investigational agent, in combination with standard of care therapies in newly diagnosed and relapsed / refractory multiple myeloma
Paris, France (Press Release) – The pivotal Phase 3 trial of isatuximab in patients with relapsed / refractory multiple myeloma met the primary endpoint of prolonging progression free survival in patients treated with isatuximab in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone alone (standard of care).
Results will be submitted to an upcoming medical meeting and are anticipated to form the basis of regulatory submissions planned for later this year.
"We are excited by these results, …
Deutsch»

Die Jahrestagung der amerikanischen Gesellschaft für Klinische Onkologie (ASCO) hat letzten Freitagmorgen begonnen und wird bis Dienstag, den 7. Juni, dauern.
Jeden Tag finden Vorträge über das multiple Myelom statt. Freitag wurden die meisten Vorträge mit neuen Forschungsergebnissen über das Myelom gehalten. Es gab neun Vorträge während einer einzelnen Nachmittagssitzung, die sich auf das multiple Myelom konzentrierten.
Außerdem gab es am Samstag, Sonntag und Montag Fortbildungssitzungen über das multiple Myelom. Darüber hinaus gab es am Sonntag eine Sitzung mit sogenannten late-braking abstracts (hochaktuellen Zusammenfassungen), die eine Präsentation über wichtige, neue Forschungsergebnisse über …
News»

The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is now history, but there's still plenty of news to report from the meeting.
In this edition of the Beacon's ASCO multiple myeloma updates, the focus is on presentations that took place the last two days of the ASCO meeting – this past Monday and Tuesday – and which concerned potential new multiple myeloma therapies.
There was a block of oral presentations related to potential new myeloma therapies that took place Tuesday morning, and all those presentations are covered in this article. …
News»

This year’s American Society of Clinical Oncology (ASCO) annual meeting began the morning of last Friday, and the meeting will run through Tuesday.
Multiple myeloma-related presentations are taking place every day of the meeting. Friday, however, was the busiest day at the meeting in terms of oral presentations with new myeloma-related research. There were nine such presentations during a single afternoon session focused on multiple myeloma.
In addition, there were myeloma-related education session presentations on Saturday, yesterday, and today. There also was a late-breaking abstract session yesterday (Sunday) with one presentation that …
News»

We hope you had a pleasant Wednesday, myeloma world.
Our Wednesday was going full steam ahead until modern technology at Myeloma Morning Headquarters decided to take a vacation. And this had to happen, of course, on a day when we have some particularly interesting developments to discuss.
What “developments” might those be, you ask?
Well, those “developments” would be the titles of all presentations to be given at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The titles were made public on Wednesday.
News, Opinion»

A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster presentations.
Therefore, it is again …
News»

This past Sunday was the second day of the American Society of Hematology’s (ASH) annual meeting, which was held in San Francisco.
As on the first day of the meeting, myeloma-related presentations once again took place during several sessions throughout the day.
A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.
While the education session was being held, a separate “scientific symposium” with two oral presentations took place in parallel. The session focused on a novel immunotherapeutic approach to treating cancer known as …